[CAS NO. 81131-70-6] Pravastatinsodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [81131-70-6]

Catalog

HY-B0165A

Brand

MCE

CAS

81131-70-6

DESCRIPTION [81131-70-6]

Overview

MDL	MFCD00887601
Molecular Weight	446.51
Molecular Formula	C23H35NaO7
SMILES	O[C@@H](C[C@@H](O)CC(O[Na])=O)CC[C@@H]([C@H](C=C1)C)[C@@](C1=C[C@@H](O)C2)([H])[C@H]2OC([C@@H](C)CC)=O

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC ₅₀ of 5.6 μM.

IC50 & Target

HMG-CoA reductase ^[1] .

In Vitro

Pravastatin (CS-514) is a member of the drug class of statins, used in combination with diet, exercise, and weight-loss for lowering cholesterol and preventing cardiovascular disease ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00456365	University of Colorado, Denver\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Polycystic Kidney, Autosomal Dominant	November 2006	Phase 3
NCT04190433	Mayo Clinic	Lymphoma	September 1, 2020	Phase 2
NCT00829309	Teva Pharmaceuticals USA	Healthy	March 2005	Phase 1
NCT02992548	Dong-A University	Chronic Kidney Disease	September 2015	Phase 4
NCT00433498	University College, London	Lung Cancer	January 2007	Phase 3
NCT00305201	Pontificia Universidad Catolica de Chile\|Bristol-Myers Squibb	Kawasaki Disease	April 2006	Phase 2
NCT01057654	University Hospital, Bonn	Hypercholesterolemia\|Hyperlipoproteinemia	January 1996	Phase 3
NCT00571194	Arkansas Children´s Hospital Research Institute	End Stage Renal Disease	September 2007	Phase 1
NCT00005010	National Institute of Allergy and Infectious Diseases (NIAID)	End-Stage Renal Disease\|Chronic Allograft Nephropathy		Phase 3
NCT01441908	MaiHealth Inc	Dyslipidemia	June 2011	Not Applicable
NCT01903694	Centre Hospitalier Universitaire Dijon	Child-Pugh A Hepatocellular Carcinoma	March 2010	Phase 3
NCT00166036	Emory University	Diabetes Mellitus\|Metabolic Syndrome X\|Hypercholesterolemia	September 2004	Phase 2
NCT00688922	Osaka Acute Coronary Insufficiency Study Group	Acute Myocardial Infarction	July 2008	Phase 4
NCT03801733	Akebia Therapeutics	Drug Interaction Potentiation	June 17, 2018	Phase 1
NCT00631189	AstraZeneca	Type IIa and IIb Hypercholesterolaemia	October 2007	Phase 4
NCT00330980	University of California, San Diego\|National Heart, Lung, and Blood Institute (NHLBI)	Dyslipidemias	April 2000	Phase 4
NCT01557075	Yonsei University	Drug-eluting Stent (DES)	July 2010	Phase 4
NCT01845428	University of North Carolina, Chapel Hill\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Nephrotic Syndrome\|Hyperlipidemia	May 2012	Phase 1
NCT00701285	JW Pharmaceutical	Chronic Heart Failure	July 2008	Phase 4
NCT03944512	The George Washington University Biostatistics Center\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|National Heart, Lung, and Blood Institute (NHLBI)	Preeclampsia\|Obstetric Labor Complications\|Hypertension in Pregnancy	July 17, 2019	Phase 3
NCT00303277	Seattle Institute for Biomedical and Clinical Research	Alzheimer´s Disease\|Aging	August 2002	Phase 4
NCT00697203	Hoffmann-La Roche	Dyslipidemia	July 2005	Phase 2
NCT00384618	Amsterdam UMC, location VUmc\|Medical Research Foundation, The Netherlands\|Bristol-Myers Squibb	Chronic Kidney Disease	May 2001	Phase 4
NCT00916747	Boston Children´s Hospital\|Schering-Plough\|Merck Sharp & Dohme LLC\|Eiger BioPharmaceuticals	Progeria	August 2009	Phase 2
NCT00382460	Bristol-Myers Squibb	Actue Coronary Syndromes	November 2000	Phase 4
NCT00982189	Hennepin Healthcare Research Institute\|American Heart Association	HIV Infection\|Cardiovascular Disease Risk	September 2009	Not Applicable
NCT00665717	Radboud University Medical Center\|Merck Sharp & Dohme LLC	HIV Infections	May 2008	Phase 1
NCT00221104	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan\|Ministry of Health, Labour and Welfare, Japan\|Hiroshima University	Ischemic Stroke	March 1, 2004	Phase 3
NCT00054938	Brigham and Women´s Hospital\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Systemic Lupus Erythematosus\|Lupus	March 2003	Phase 2
NCT01146106	Dr. Reddy´s Laboratories Limited	Healthy	December 2002	Phase 1
NCT04284657	University of Southern California	Autosomal Dominant Polycystic Kidney Disease	January 30, 2019	Phase 2
NCT02518516	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Hypercholesterolemia	January 2011
NCT02079974	Dr. Robert F. Casper\|Toronto Centre for Advanced Reproductive Technology	Endometriosis	July 2014	Not Applicable
NCT05107063	Daiichi Sankyo, Inc.\|Daiichi Sankyo Korea Co., Ltd.	Dyslipidemia Associated With Type II Diabetes Mellitus	January 20, 2016
NCT01717586	The University of Texas Medical Branch, Galveston\|University of Pittsburgh\|Northwestern University\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Preeclampsia	August 2012	Phase 1
NCT01816997	Taipei Veterans General Hospital, Taiwan	Diabetes	January 2012	Phase 4
NCT00107523	Fred Hutchinson Cancer Center	Leukemia	January 2005	Phase 1
NCT02360826	Children´s Mercy Hospital Kansas City\|American Heart Association	Drug Distribution	June 17, 2014	Phase 1
NCT00467831	National Human Genome Research Institute (NHGRI)\|National Institutes of Health Clinical Center (CC)	Hermansky-Pudlak Syndrome (HPS)\|Pulmonary Fibrosis\|Oculocutaneous Albinism\|Platelet Storage Pool Deficiency\|Metabolic Disease	April 2007	Phase 1\|Phase 2
NCT00654537	AstraZeneca	Hypercholesterolemia	April 2001	Phase 3
NCT00459745	Shionogi\|Integrium\|Shionogi Inc.	Combined Hyperlipidemia	April 2007	Phase 3
NCT02621957	Genentech, Inc.	Breast Cancer	December 2015	Phase 1
NCT00702130	University of Thessaly	Ventilator Associated Pneumonia	June 2008	Early Phase 1
NCT00834379	Teva Pharmaceuticals USA	Healthy	September 2000	Phase 1
NCT00830258	Teva Pharmaceuticals USA	Healthy	April 2005	Phase 1
NCT04425902	ViiV Healthcare	HIV Infections	December 16, 2020	Phase 1
NCT00639223	University of Pennsylvania\|Chestnut Hill Health System	Hypercholesterolemia\|Statin-Associated Myopathy	January 2008	Phase 2
NCT01146093	Dr. Reddy´s Laboratories Limited	Healthy	November 2002	Phase 1
NCT03219372	Cedars-Sinai Medical Center\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)	Hepatocellular Carcinoma\|Liver Cirrhoses	September 27, 2018	Phase 2
NCT02456844	Bristol-Myers Squibb	Rheumatoid Arthritis	May 2015	Phase 1
NCT03456102	Johns Hopkins University	Tuberculosis	March 9, 2020	Phase 2
NCT01301066	Kowa Research Institute, Inc.\|Kowa Pharmaceuticals America, Inc.\|Eli Lilly and Company	Dyslipidemia	December 2010	Phase 4
NCT02229773	Boehringer Ingelheim	Healthy	January 2000	Phase 1
NCT00688896	Akros Pharma Inc.	Type II Hyperlipidemia	June 2002	Phase 2
NCT01831232	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Refractory Anemia With Excess Blasts\|Untreated Adult Acute Myeloid Leukemia	May 2013	Not Applicable
NCT01342887	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	April 2011	Phase 1\|Phase 2
NCT01857921	Yonsei University	Coronary Artery	December 2010	Not Applicable
NCT01268202	Gustave Roussy, Cancer Campus, Grand Paris\|Ministry of Health, France	Fibrosis	December 17, 2010	Phase 2
NCT03273413	University of Colorado, Denver	ADPKD\|Autosomal Dominant Polycystic Kidney	August 31, 2017	Phase 4
NCT00650221	Mylan Pharmaceuticals Inc\|Genpharm ULC\|MylanPharma	Therapeutic Equivalency	June 2003	Phase 1
NCT01254461	AstraZeneca	Drug Interaction	February 2011	Phase 1
NCT00006412	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Lipodystrophy		Phase 3
NCT00549926	Yokohama City University Medical Center	Coronary Disease\|Hypercholesterolemia	October 2007	Phase 4
NCT00599625	University of Virginia\|American College of Gastroenterology	Crohn´s Disease	October 2004	Not Applicable
NCT00227500	Kirby Institute\|The University of New South Wales\|National Heart, Lung, and Blood Institute (NHLBI)\|Garvan Institute of Medical Research\|St Vincent´s Hospital, Sydney	HIV Infections\|Lipid Metabolism\|Glucose Metabolism\|Metabolic Abnormality\|Lipodystrophy\|Cardiovascular Disease	July 2001	Phase 4
NCT03648970	Universitas Airlangga	Pre-Eclampsia	March 1, 2018	Phase 2
NCT02266485	Boehringer Ingelheim	Healthy	July 1998	Phase 1
NCT00039663	National Institutes of Health Clinical Center (CC)	HIV Infections	May 2002	Phase 1
NCT03073018	University Medical Center Groningen\|Dutch Kidney Foundation\|Netherlands Heart Foundation	Microalbuminuria\|Cardiovascular Diseases\|Renal Disease	April 1998	Phase 3
NCT00000542	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Diabetes Mellitus\|Heart Diseases\|Hypercholesterolemia\|Hypertension\|Myocardial Infarction\|Myocardial Ischemia\|Heart Failure	August 1993	Phase 3
NCT04719481	Peking University Third Hospital	Postmenopausal Osteoporosis	November 2021	Phase 4
NCT03882177	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis\|Pulmonary Tuberculosis	February 21, 2020	Phase 2
NCT00362206	Solvay Pharmaceuticals	Hyperlipidemia	September 2006	Phase 3
NCT01958489	Eli Lilly and Company	Healthy Volunteers	October 2013	Phase 1
NCT02431013	Ajou University School of Medicine	Dyslipidemias\|Peripheral Artery Disease	April 2015	Phase 1
NCT00000941	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 1
NCT02518503	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Diabetes Mellitus, Type 2\|Cardiovascular Disease	July 2012
NCT00000461	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Heart Diseases\|Myocardial Ischemia	December 1986	Phase 2
NCT01856374	Yonsei University	Multi-vessel Diseases, Angina	August 2011	Phase 4
NCT01075555	Federation Francophone de Cancerologie Digestive\|Centre Hospitalier Universitaire Dijon	Liver Cancer	February 2010	Phase 3
NCT00738296	Hospital Universitario 12 de Octubre\|Merck Sharp & Dohme LLC\|Hospital Regional 1o de Octubre	Cardiovascular Diseases	April 2005	Phase 4
NCT01602913	GlaxoSmithKline	Depression, Postpartum	December 2011
NCT03510715	Sanofi\|Regeneron Pharmaceuticals	Hypercholesterolemia	August 31, 2018	Phase 3
NCT00731016	Assistance Publique Hopitaux De Marseille	Hutchinson-Gilford Progeria Syndrome	October 2008	Phase 2
NCT00214604	AstraZeneca	Hyperlipoproteinemia Type III	February 2005	Phase 3
NCT00117494	French National Agency for Research on AIDS and Viral Hepatitis	Hyperlipidemia\|HIV Infections	October 2005	Phase 4
NCT00840177	Southwest Oncology Group\|National Cancer Institute (NCI)	Leukemia	August 2009	Phase 2
NCT00177580	University of Pittsburgh\|Stanley Medical Research Institute	Schizophrenia\|Schizoaffective Disorder	July 2003	Phase 4
NCT04640571	University of Maryland, Baltimore	Bile Salt Export Pump (BSEP) Transporter\|Polysorbate 80	April 1, 2021	Phase 4
NCT00257686	Kowa Research Europe	Hypercholesterolemia or Combined Dyslipidemia	September 2005	Phase 3
NCT02754739	Samsung Medical Center\|Daiichi Sankyo Korea Co., Ltd.	Diabetes Mellitus\|Prediabetic State	April 15, 2014	Phase 4
NCT01173939	Positive Trial Group	Hypercholesterolemia\|Type 2 Diabetes\|Hypertension	July 2010	Not Applicable
NCT04356209	Institut du Cancer de Montpellier - Val d´Aurelle	Breast Cancer	September 28, 2020	Phase 2
NCT01082588	Massachusetts General Hospital\|Stanley Medical Research Institute\|North Suffolk Mental Health Association	Schizophrenia\|Schizoaffective Disorders\|Schizophreniform Disorders	June 2010	Phase 4
NCT01515813	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection	November 2011	Phase 2
NCT00200655	Nantes University Hospital	Relapsing-remitting Multiple Sclerosis	December 2004	Phase 3
NCT00879034	Boston Children´s Hospital\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Schering-Plough	Progeria\|Hutchinson-Gilford Syndrome	March 2009	Phase 2
NCT03510884	Sanofi\|Regeneron Pharmaceuticals	Hypercholesterolaemia	May 31, 2018	Phase 3
NCT01788254	Matthias Schwab\|University Hospital Tuebingen	Genotype-related Drug Metabolism	January 2012	Phase 1
NCT01845194	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH	Drug Biotransformation\|Membrane Transport	December 2009	Phase 1
NCT01502904	Yonsei University	Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension	July 2010	Phase 4
NCT02841774	Matthew Feinstein\|Northwestern University	HIV Infection\|Coronary Heart Disease	November 2016	Phase 2
NCT00221754	University Hospital, Bordeaux\|Ministry of Health, France	HIV Infection\|Hypercholesterolemia	March 2003	Phase 2
NCT00529178	Bristol-Myers Squibb	Hypercholesterolemia	December 2002	Phase 4
NCT00132717	Organon and Co	Hypercholesterolemia	January 1, 2005	Phase 3
NCT04608344	Gilead Sciences\|Galapagos NV	Rheumatoid Arthritis	November 4, 2020	Phase 1
NCT00738972	Fundación Lindavista del Corazón AC	Hypertension	January 2008	Phase 3
NCT00005117	National Center for Research Resources (NCRR)	Heart Diseases		Not Applicable
NCT00017758	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|HIV Seronegativity\|Lipodystrophy		Phase 1
NCT05524246	Children´s Hospital Medical Center, Cincinnati	Hematopoietic Stem Cell Transplant (HSCT)\|Endothelial Injury	November 2022	Phase 1
NCT02484261	Reuven Schore\|Millennium Pharmaceuticals, Inc.\|Hyundai Hope On Wheels\|Children´s National Research Institute	Leukemia	May 2015	Phase 1
NCT00843661	Ospedale di Circolo - Fondazione Macchi\|Merck Sharp & Dohme LLC	HIV\|Hyperlipidemia\|HIV Infections	March 2009	Phase 4
NCT00000539	National Heart, Lung, and Blood Institute (NHLBI)	Arterial Occlusive Diseases\|Cardiovascular Diseases\|Heart Diseases\|Vascular Diseases\|Diabetes Mellitus	September 1992	Phase 3
NCT00755352	Daiichi Sankyo, Inc.	Hypercholesterolemia	November 2002	Phase 4
NCT01418729	Hospital Donostia\|INSTITUTO BIODONOSTIA	Advanced Hepatocarcinoma	September 2011	Phase 2
NCT00834847	Teva Pharmaceuticals USA	Healthy	August 2000	Phase 1
NCT03131973	Bristol-Myers Squibb	Rheumatoid Arthritis	May 13, 2017	Phase 1
NCT00380939	Pfizer	Coronary Arteriosclerosis	April 1999	Phase 4
NCT01038154	Hospital Donostia	Esophageal Cancer\|Stomach Cancer	November 2009	Phase 4
NCT01256476	Kowa Research Institute, Inc.	Primary Dyslipidemia\|Mixed Dyslipidemia	October 2010	Phase 4
NCT02155530	Yonsei University	Coronary Artery Disease	June 2014	Not Applicable
NCT01857843	Yonsei University	Acute Coronary Syndrome	November 2009	Phase 4
NCT02871687	Brigham and Women´s Hospital	Healthy Subjects	April 2016	Phase 1
NCT00630734	University of Colorado, Denver\|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA	HIV Infections\|Hyperlipidemia	February 2008	Phase 4
NCT01497483	University of California, San Francisco\|National Institute of General Medical Sciences (NIGMS)	Healthy	December 2011	Phase 1
NCT01872845	Yonsei University	Coronary Artery Occlusive Disease	June 12, 2013	Not Applicable
NCT01357486	University Hospital, Bordeaux\|Federation Francophone de Cancerologie Digestive\|UNICANCER	Hepatocellular Carcinoma\|CHILD B	November 14, 2011	Phase 2
NCT02547402	Complexa, Inc.	Acute Kidney Injury	December 2015	Phase 1
NCT00648544	Mylan Pharmaceuticals Inc\|Genpharm ULC\|MylanPharma	Therapeutic Equivalency	July 2003	Phase 1

Appearance

Solid

Source

Penicillium Citrinum

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 223.96 mM ; Need ultrasonic)

H ₂ O : ≥ 50 mg/mL ( 111.98 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2396 mL	11.1980 mL	22.3959 mL
5 mM	0.4479 mL	2.2396 mL	4.4792 mL
10 mM	0.2240 mL	1.1198 mL	2.2396 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (223.96 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89.

Synonyms

1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, sodium salt (1:1), (βR,δR,1S,2S,6S,8S,8aR)-

1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S-[1α(βS*,δS*),2α,6α,8β(R*),8aα]]-

1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, monosodium salt, (βR,δR,1S,2S,6S,8S,8aR)-

CS 514

SQ 31000

Epastatin sodium

Pravastatin sodium

Mevalotin

Pravachol

Sodium pravastatin

Pravastatin sodium salt

Pravacol

Vasten

Lipostat

Selektine

Elisor

Pravasine

Liprevil

Prava

Pravaselect

Pravasin

Selipran

Selectin

Lipidal

Oliprevin

3β-Hydroxycompactin sodium salt

Eptastatin sodium

Mevan

Pravator

Pravastin